100% Free CCDM Exam Dumps to Pass Exam Easily from TestkingPDF
Free CCDM Exam Questions CCDM Actual Free Exam Questions
NEW QUESTION # 76
An international study collects lab values. Sites use different units in the source documents. Which of the following data collection strategies will have fewer transcription errors?
- A. Use a structured field and print standard units on the data collection form
- B. Have all sites convert the values to the same unit system on the data collection form
- C. Allow values to be entered as they are in the source and the selection of units on the data collection form
- D. Allow values to be entered as they are in the source document and derive the units based on the magnitude of the value
Answer: C
Explanation:
In international or multicenter clinical studies, laboratory data often originate from different laboratories that use varying measurement units (e.g., mg/dL vs. mmol/L). The Good Clinical Data Management Practices (GCDMP, Chapter on CRF Design and Data Collection) provides clear guidance on managing this variability to ensure data consistency, traceability, and minimized transcription errors.
The approach that results in fewer transcription errors is to allow sites to enter lab values exactly as recorded in the source document (original lab report) and to require explicit selection of the corresponding unit from a predefined list on the data collection form or within the electronic data capture (EDC) system. This method (Option B) preserves the original source data integrity while enabling centralized or automated unit conversion later during data cleaning or statistical processing.
Option B also supports compliance with ICH E6 (R2) Good Clinical Practice (GCP), which mandates that transcribed data must remain consistent with the source documents. Attempting to derive units automatically (Option A) can lead to logical errors, while forcing sites to manually convert units (Option D) introduces unnecessary complexity and increases the risk of miscalculation or inconsistent conversions. Printing only standard units on the CRF (Option C) ignores local lab practices and can lead to discrepancies between CRF entries and source records, triggering numerous data queries.
The GCDMP emphasizes that CRF design must account for local variations in measurement systems and ensure that unit selection is structured (dropdowns, controlled lists) rather than free-text to prevent typographical errors and facilitate standardization during data transformation.
Therefore, Option B-"Allow values to be entered as they are in the source and the selection of units on the data collection form"-is the most compliant, accurate, and efficient strategy for minimizing transcription errors in international lab data collection.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 5.4 - Laboratory Data Management and Unit Handling ICH E6 (R2) Good Clinical Practice, Section 5.18 - Data Handling and Record Retention CDISC SDTM Implementation Guide, Section 6.3 - Handling of Laboratory Data and Standardized Units FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6 - Source Data and Accuracy of Data Entry
NEW QUESTION # 77
A study team member states that data entry can be done by clerical personnel at sites. Which are important considerations?
- A. Historically in clinical research site study coordinator roles have been filled by people with clinical or clinical research experience
- B. The person at the sites who enters the data usually also understands which data in the medical record are needed for the study, where to find them and which value to choose
- C. It is possible that clerical personnel could be hired by sites because data entry requires little training and use of clerical personnel would reduce burden on sites
- D. Data entry at sites requires study-specific training on how to use the EDC system to enter data and respond to data discrepancies identified by the system
Answer: D
Explanation:
Although clerical staff can technically perform data entry, data entry in clinical research requires study-specific training, particularly in the use of the Electronic Data Capture (EDC) system and understanding data discrepancy resolution procedures.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: CRF Design and Data Collection) and ICH E6 (R2), individuals responsible for data entry at clinical sites must be qualified by education, training, and experience. This includes understanding how to navigate the EDC system, enter data according to CRF Completion Guidelines, and appropriately respond to queries or system-generated edit checks.
Untrained clerical personnel may inadvertently introduce errors, violate Good Clinical Practice (GCP) standards, or fail to recognize protocol-relevant data. Therefore, the Data Manager must ensure that site users receive study-specific and system training before gaining access to the EDC environment.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 5.2 - Investigator Site Training and Data Entry Requirements ICH E6 (R2) Good Clinical Practice, Section 4.1.5 - Qualified Personnel and Training Requirements FDA 21 CFR Part 11 - User Access and Training Provisions for Electronic Records
NEW QUESTION # 78
Which of the following data verification checks would most likely be included in a manual or visual data review step?
- A. Checking an entered value against a valid list of values
- B. Checking mandatory fields for missing values
- C. Checking a value against a reference range
- D. Checking adverse event treatments against concomitant medications
Answer: D
Explanation:
Manual or visual data review is used to identify complex clinical relationships and contextual inconsistencies that cannot be detected by automated edit checks.
According to the GCDMP (Chapter: Data Validation and Cleaning), automated edit checks are ideal for structured validations, such as missing fields (option C), reference ranges (option D), or predefined value lists (option A). However, certain clinical cross-checks-such as verifying adverse event treatments against concomitant medication records-require clinical judgment and contextual understanding.
For example, if an adverse event of "severe headache" was reported but no analgesic appears in the concomitant medication log, the data may warrant manual review and query generation. These context-based checks are best performed by trained data reviewers or medical data managers during manual data review cycles.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.3 - Manual Review and Clinical Data Consistency Checks ICH E6 (R2) Good Clinical Practice, Section 5.18.4 - Clinical Data Review Responsibilities FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Data Verification Principles
NEW QUESTION # 79
A relational database has tables for PATIENT_DEMOGRAPHY and VITAL_SIGNS data collected during a visit. The primary key for the VITAL_SIGNS table is a composite key that includes the unique patient identifier, visit number, and vital signs parameter name. The two tables are joined on the patient identifier. What will be the number of records in the result set?
- A. One record per patient per visit
- B. One record per patient per visit per vital sign parameter
- C. One record per visit
- D. One record per patient
Answer: B
Explanation:
In a relational database structure, each record in a table is uniquely identified by a primary key. In this case, the VITAL_SIGNS table uses a composite primary key consisting of:
Patient Identifier,
Visit Number, and
Vital Signs Parameter Name.
This means each record represents a unique measurement of a specific parameter (e.g., blood pressure, pulse) for a patient at a specific visit.
When joining PATIENT_DEMOGRAPHY and VITAL_SIGNS tables on the patient identifier, the result set will include one record for every combination of patient, visit, and parameter - i.e., one record per patient per visit per vital sign parameter.
Therefore, option C correctly describes the expected number of records.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Design and Build, Section 5.2 - Primary and Foreign Key Relationships in Relational Models CDISC SDTM Implementation Guide, Section 5.3 - Observation-Level Data Structures ICH E6(R2) GCP, Section 5.5.3 - Data Organization and Integration Principles
NEW QUESTION # 80
Which of the following tasks would be reasonable during a major upgrade of a clinical data management system?
- A. All of the data formats in the archive should be updated to new standards.
- B. The ability to access and read the clinical data archive should be tested.
- C. The data archive should be migrated to an offsite database server.
- D. All of the case report forms should be pulled and compared to the archive.
Answer: B
Explanation:
During a major system upgrade, it is critical to verify that archived data remain accessible, readable, and intact following the implementation.
According to the GCDMP (Chapter: Database Lock and Archiving), regulatory requirements such as 21 CFR Part 11 and ICH E6(R2) mandate that archived data must remain retrievable in a human-readable format for the duration of retention (often years after study completion).
Therefore, as part of validation and verification testing, organizations must confirm that existing archives can still be accessed using the upgraded system or compatible tools.
Option A: Updating archive formats could alter original data integrity (noncompliant).
Option C: Migration offsite is an IT infrastructure task, not directly tied to the upgrade process.
Option D: Comparing CRFs to archives is unnecessary unless data corruption is suspected.
Hence, option B (testing archive accessibility) is the correct and compliant approach.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Lock and Archiving, Section 5.4 - System Upgrades and Archive Validation ICH E6(R2) GCP, Section 5.5.3 - System Validation and Data Retention FDA 21 CFR Part 11 - Data Archiving, Retention, and Retrieval Requirements
NEW QUESTION # 81
A data manager takes the INTERSECTION data in two tables wanting only the 50 records common to both tables. What operation did the data manager perform?
- A. Inner join
- B. Full outer join
- C. Left outer join
- D. Right outer join
Answer: A
Explanation:
The inner join operation retrieves only the records that exist in both tables, which is the intersection of two datasets.
In clinical data management, relational databases often store related data in multiple tables-for example, demographic data in one table and lab results in another. When a Data Manager needs to extract records that exist in both (e.g., subjects appearing in both demographics and labs), an inner join is used.
According to the GCDMP (Chapter: Database Design and Build), joins are fundamental relational operations ensuring data consistency and integrity across multiple data domains.
Inner join: Returns matching records from both tables (intersection).
Left/right outer joins: Return all records from one table and matching records from the other (preserving nonmatches).
Full outer join: Returns all records from both tables, whether matched or not.
Therefore, to select only the 50 records common to both tables, the correct operation is an inner join.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Design and Build, Section 4.3 - Relational Database Concepts and Joins ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Data Processing and Validation
NEW QUESTION # 82
What does 21 CFR Part 11 dictate in regards to a minimum expectation of EDC training prior to access?
- A. Training must include an exam
- B. Training must be in the user's native language
- C. Training must be performed
- D. Training must be face to face
Answer: C
Explanation:
Under FDA 21 CFR Part 11, organizations using electronic systems must ensure that all system users are trained to perform their assigned functions before gaining access to the system. The regulation requires documented evidence of training but does not specify how it should be conducted (e.g., exam-based, in person, or language-specific).
The GCDMP (Chapter: Computerized Systems and Compliance) further clarifies that personnel training should include instruction on system functionality, audit trails, data entry procedures, and electronic signatures to maintain compliance and data integrity. Training must be performed and documented but does not require a specific format or delivery method.
Therefore, option A-Training must be performed-is correct, as it reflects the minimum regulatory expectation per FDA and SCDM standards.
Reference (CCDM-Verified Sources):
FDA 21 CFR Part 11, Section 11.10(i) - Personnel Training Requirements
SCDM GCDMP, Chapter: Computerized Systems and Compliance, Section 5.4 - System Training and Documentation ICH E6(R2) GCP, Section 2.8 - Qualified Personnel and Training Requirements
NEW QUESTION # 83
Which is a minimum prerequisite that should be in place before choosing an EDC system?
- A. Updated governance documentation
- B. Draft validation plan
- C. Knowledge of functional requirements
- D. Completed installation qualification
Answer: C
Explanation:
Before selecting an Electronic Data Capture (EDC) system for a clinical trial, it is essential to have a clear understanding of the functional requirements. This serves as the minimum prerequisite to guide system selection, ensuring that the EDC solution aligns with the protocol needs, data workflow, security requirements, and regulatory compliance.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Computerized Systems and Compliance), functional requirements describe what the system must do-such as data entry capabilities, edit checks, query management, user roles, audit trails, and integration with external systems (e.g., labs, ePRO). This understanding allows sponsors and CROs to evaluate vendor systems effectively during the selection and qualification phase.
Other options:
B . Installation qualification and D. Validation plan occur after system selection.
C . Governance documentation supports operations but is not required before choosing the system.
Hence, option A is correct - the first and most essential prerequisite before EDC selection is a solid understanding of the functional requirements.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Computerized Systems and Compliance, Section 4.2 - Requirements Gathering and System Selection FDA 21 CFR Part 11 - System Validation and Intended Use Requirements ICH E6(R2) GCP, Section 5.5.3 - Computerized System Selection and Qualification
NEW QUESTION # 84
A Data Manager receives an audit finding of missing or undocumented training for two database developers according to the organization's training SOP and matrix. Which is the best response to the audit finding?
- A. Send the two developers to the required training
- B. Remove the training items from the training matrix
- C. Reprimand the person responsible for maintaining training documentation
- D. Identify the root cause and improve the process to prevent it
Answer: D
Explanation:
When an audit identifies missing or undocumented training, the most appropriate and compliant response is to identify the root cause of the issue and implement corrective and preventive actions (CAPA) to ensure that similar findings do not recur.
According to Good Clinical Data Management Practices (GCDMP, Chapter: Quality Management and Auditing), effective quality systems require root cause analysis (RCA) for all audit findings. The process involves:
Investigating why the documentation gap occurred (e.g., poor tracking, outdated SOP, or lack of oversight).
Correcting the immediate issue (e.g., ensuring the developers complete or document training).
Updating processes, training systems, or oversight mechanisms to prevent recurrence.
While sending the two developers to training (D) addresses the symptom, it does not resolve the systemic issue identified by the audit. Options B and C are non-compliant and do not address quality system improvement.
Therefore, option A (Identify the root cause and improve the process) is the best and CCDM-compliant response.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Quality Management and Auditing, Section 6.2 - Corrective and Preventive Actions (CAPA) ICH E6(R2) GCP, Section 5.1.1 - Quality Management and Continuous Process Improvement FDA 21 CFR Part 820.100 - Corrective and Preventive Action (CAPA) Requirements
NEW QUESTION # 85
To ensure data quality and efficient integration of data, which of the following best describes the main topic that should be covered in initial discussions with a vendor providing the external data?
- A. Metrics that will be used to measure data quality
- B. Criteria to trigger audits based on performance-monitoring reports
- C. Standard dictionary versioning and maintenance
- D. Acceptable record, field, and file formats
Answer: D
Explanation:
In initial vendor discussions for external data integration (e.g., central lab, ECG, imaging vendors), the most critical and foundational topic is defining the acceptable record, field, and file formats.
According to the GCDMP (Chapter: External Data Transfers and Integration), establishing the Data Transfer Specifications (DTS) early in the process ensures consistent structure, proper mapping, and compatibility between the vendor's system and the sponsor's database. These specifications define:
Data structure (variable names, formats, delimiters)
File naming conventions
Frequency of transfers
Methods of secure data transmission
Discussing formats first allows later alignment on data validation, quality metrics, and dictionary standards (which occur in subsequent stages). Without format agreement, all downstream processes risk misalignment, resulting in data incompatibility and rework.
Thus, option C (Acceptable record, field, and file formats) correctly represents the foundational focus of initial vendor discussions for ensuring data quality and integration efficiency.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: External Data Transfers and Integration, Section 4.1 - Data Transfer Planning and Specification Development ICH E6(R2) GCP, Section 5.5.3 - Data Handling and System Validation FDA Guidance: Computerized Systems Used in Clinical Investigations, Section 6.3 - Data Import and Format Control
NEW QUESTION # 86
Data characterizing the safety profile of a drug are collected to provide information for which of the following?
- A. Survival curves
- B. Efficacy meta-analyses
- C. Quality of life calculations
- D. Product labeling
Answer: D
Explanation:
Safety data collected during a clinical trial are used primarily to support product labeling, ensuring accurate communication of a drug's risks, contraindications, and adverse reactions to healthcare providers and patients.
According to the GCDMP (Chapter: Safety Data Handling and Reconciliation) and ICH E2A/E2F guidelines, all adverse events (AEs), serious adverse events (SAEs), and laboratory abnormalities are analyzed and summarized to define the safety profile of an investigational product. These data form the basis for regulatory submissions such as the Clinical Study Report (CSR) and product labeling (e.g., prescribing information), as required by the FDA and other regulatory authorities.
While safety data may contribute indirectly to analyses such as survival curves (option A) or quality of life metrics (option D), their primary regulatory function is to inform product labeling and post-marketing surveillance documentation.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Safety Data Handling and Reconciliation, Section 4.3 - Use of Safety Data in Regulatory Submissions ICH E2A - Clinical Safety Data Management: Definitions and Standards for Expedited Reporting FDA Guidance for Industry: Adverse Event Reporting and Labeling Requirements
NEW QUESTION # 87
Every database lock should follow documented approval of which stakeholders?
- A. Clinical/Scientific Representative, Data Manager
- B. Clinical/Scientific Representative, Data Manager, Biostatistician
- C. Clinical/Scientific Representative, Biostatistician
- D. Clinical/Scientific Representative, Biostatistician, Programmer
Answer: B
Explanation:
According to the Good Clinical Data Management Practices (GCDMP), the database lock (DBL) process signifies the formal closure of the clinical trial database, ensuring that no further changes can be made to the data before statistical analysis. This process must be documented, controlled, and approved by key study stakeholders to ensure data accuracy, completeness, and readiness for analysis.
The GCDMP specifies that database lock should occur only after all data cleaning, discrepancy resolution, and reconciliation activities are complete. The lock authorization typically requires the approval of the Clinical/Scientific Representative (to confirm clinical completeness), the Data Manager (to confirm data integrity and query closure), and the Biostatistician (to confirm readiness for statistical analysis).
This tri-party approval ensures that the database reflects final, verified data consistent with the clinical protocol, and that the statistical analysis dataset derived from the database is accurate and auditable. The approval process is documented via a Database Lock Authorization Form or Sign-off Log, which becomes part of the permanent trial master file (TMF).
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Lock and Archiving, Section 7.1 - Lock Procedures and Approvals ICH E6 (R2) GCP, Section 5.5.3 - Data Handling and Record Keeping FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Section on Database Closure
NEW QUESTION # 88
A study numbers subjects sequentially within each site and does not reuse site numbers. Which information is required when joining data across tables?
- A. Subject number
- B. Subject number and site number
- C. Site number
- D. Study number and subject number
Answer: B
Explanation:
When subjects are numbered sequentially within each site, it means that the subject identification numbers (Subject IDs) restart from 001 at each site. For example, Site 101 may have Subject 001, and Site 102 may also have a Subject 001. In such cases, the subject number alone is not globally unique across the entire study. Therefore, when integrating or joining data across multiple database tables (for example, linking demographic, adverse event, and laboratory data), both the site number and the subject number are required to create a unique key that accurately identifies each record.
According to the Good Clinical Data Management Practices (GCDMP, Chapter on CRF Design and Data Collection), every data record in a clinical trial database must be uniquely and unambiguously identified. This is typically achieved through a composite key, combining identifiers such as site number, subject number, and sometimes study number. The GCDMP specifies that a robust data structure must prevent duplication or mislinking of records across domains or tables.
Furthermore, FDA and CDISC standards (SDTM model) also emphasize the importance of unique subject identifiers (USUBJID), which are derived from concatenating the study ID, site ID, and subject ID. This ensures traceability, integrity, and accuracy of subject-level data during database joins, data exports, and regulatory submissions.
Thus, in the described scenario, since subject numbering restarts at each site, both the site number and subject number are required to uniquely identify and correctly join subject data across different datasets or tables.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 4.1 - Unique Subject Identification CDISC SDTM Implementation Guide, Section 5.2 - Subject and Site Identification (Variable: USUBJID) FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6 - Data Integrity and Record Identification
NEW QUESTION # 89
What are the first logical specifications that need approval when building an efficient EDC database?
- A. eCRF Fields
- B. Edit Check Logic
- C. eCRF Guidelines
- D. Metric Reports
Answer: A
Explanation:
In the EDC database build process, the first logical specifications that require approval are the electronic Case Report Form (eCRF) fields.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Database Design and Build), eCRF field specifications define what data elements are collected, their data types, permitted values, field lengths, and any associated metadata. Approval of these specifications forms the foundation for subsequent design components such as edit check programming, query management rules, and data validation logic.
Edit checks (B) are developed only after fields and structures are finalized.
Metric reports (C) and eCRF guidelines (D) are downstream documentation or tools, not logical specifications required at the build start.
Therefore, option A (eCRF fields) is correct, as their approval marks the first formal milestone in the EDC system development life cycle.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Design and Build, Section 4.2 - Logical Design and eCRF Field Specifications ICH E6(R2) GCP, Section 5.5.3 - System Design and Validation Documentation FDA 21 CFR Part 11 - System Validation and Documentation Controls
NEW QUESTION # 90
Which data are needed to monitor site variability in eligibility screening?
- A. Number of subjects enrolled
- B. Number of sites with low enrollment
- C. Number of sites with high enrollment
- D. Number of subjects screened and number of subjects enrolled
Answer: D
Explanation:
To monitor site variability in eligibility screening, you must analyze the number of subjects screened versus the number of subjects enrolled at each site. This allows identification of sites that are over- or under-screening relative to their enrollment yield.
The GCDMP (Chapter: Data Quality Assurance and Metrics) emphasizes that screening-to-enrollment ratios are critical indicators of protocol compliance and data quality. Sites with unusually low conversion rates may have unclear understanding of inclusion/exclusion criteria, requiring targeted training or monitoring.
Other options (A, C, D) provide enrollment metrics but do not reveal screening efficiency or variability, which depend on both screening and enrollment data.
Thus, option B correctly identifies the data necessary for monitoring eligibility screening performance across sites.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Quality Assurance and Metrics, Section 5.4 - Site Performance Metrics ICH E6(R2) GCP, Section 5.18 - Monitoring and Site Oversight Requirements
NEW QUESTION # 91
Which competency is necessary for EDC system use in a study using the medical record as the source?
- A. Using ePRO devices
- B. Resolving discrepant data
- C. Training on how to log into Medical Records system
- D. Screening study subjects
Answer: C
Explanation:
In studies where the medical record serves as the source document, the Electronic Data Capture (EDC) system users (typically study coordinators or site personnel) must have appropriate training on how to access and log into the medical record system. This competency ensures that data abstracted from the electronic medical record (EMR) are complete, accurate, and verifiable in compliance with Good Clinical Practice (GCP) and Good Clinical Data Management Practices (GCDMP).
According to the GCDMP (Chapter: EDC Systems and Data Capture) and ICH E6(R2), all personnel involved in data entry and verification must be trained in both the EDC and the primary source systems (e.g., EMR). This ensures that the integrity of data flow-from source to EDC-is maintained, and that personnel understand system access controls, audit trails, and proper documentation of source verification.
While resolving discrepant data (C) and screening subjects (A) are part of study operations, the competency directly related to EDC system use in EMR-based studies is the ability to properly log into and navigate the medical records system to extract source data.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Electronic Data Capture (EDC), Section 5.1 - Source Data and System Access Requirements ICH E6(R2) Good Clinical Practice, Section 4.9 - Source Documents and Data Handling FDA Guidance: Use of Electronic Health Record Data in Clinical Investigations, Section 3 - Investigator Responsibilities
NEW QUESTION # 92
Electronic submission standards require that an individual subject's complete CRF should be provided as what type of file:
- A. Microsoft Word (.docx)
- B. Portable Document Format (.pdf)
- C. Rich Text Format (.rtf)
- D. Statistical Analysis System (.sas)
Answer: B
Explanation:
Electronic submission standards, as established by FDA, CDISC, and ICH, require that an individual subject's complete Case Report Form (CRF) be submitted as a Portable Document Format (.pdf) file. The PDF format is universally recognized and accepted because it ensures that the structure, format, and visual fidelity of the CRF are preserved exactly as originally designed, regardless of software or hardware environment.
According to the FDA Guidance for Industry: Providing Regulatory Submissions in Electronic Format (2006) and CDISC SDTM standards, sponsors must include a subject-level CRF in PDF form for each participant in the submission dataset. This requirement ensures that reviewers can trace data points from analysis datasets back to their source entries in the CRF, fulfilling the principles of data traceability and transparency.
The Good Clinical Data Management Practices (GCDMP) also support this requirement, emphasizing that CRF archiving should maintain readability and regulatory accessibility. Formats like RTF, DOCX, or SAS datasets are not acceptable substitutes for regulatory CRF submission because they may alter formatting, structure, or introduce modifiable content, violating FDA data integrity principles.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Archiving and Submission FDA Guidance for Industry: Providing Regulatory Submissions in Electronic Format, April 2006 CDISC SDTM Implementation Guide, Section 5.3 - CRF Representation and Traceability
NEW QUESTION # 93
Which is the best reason why front-end checks are usually kept minimal, when compared to back-end checks, in a paper-based clinical study?
- A. There is no need to alert the site personnel immediately about a data issue, as the study has happened already
- B. There are approvals required to raise a Data Clarification Form which could take time
- C. Data review can be performed at a later time due to the paper-based studies being smaller in size
- D. Data entry staff should be able to enter a value into the database just as it appears in the paper CRF
Answer: D
Explanation:
In paper-based clinical studies, front-end data checks (those performed during data entry) are intentionally kept minimal to ensure that data are entered exactly as recorded on the paper CRF. This principle ensures data integrity by maintaining fidelity between source and electronic records before any cleaning or edit validation occurs.
The GCDMP (Chapter: Data Validation and Cleaning) explains that data entry operators should input values as written, even if they appear incorrect or inconsistent, because the purpose of front-end checks is not to interpret but to capture data faithfully. The back-end edit checks-performed later by data managers-are designed to identify inconsistencies, out-of-range values, or logical errors that require clarification through queries.
This approach separates data capture from data cleaning, minimizing bias and preserving original investigator input. Hence, option A accurately states the rationale for keeping front-end checks minimal in paper-based studies.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 4.2 - Data Entry, Edit Checks, and Query Process ICH E6(R2) GCP, Section 5.5.3 - Data Handling and System Controls FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.1 - Data Entry and Verification Processes
NEW QUESTION # 94
A study is collecting pain levels three times a day. Which is the best way to collect the data?
- A. Using paper pain diary cards completed by study subjects
- B. Using ePRO with reminders for data collection at each time point
- C. Sites calling patients daily and administering a pain questionnaire
- D. Study subjects calling into an IVRS three times a day to enter pain levels
Answer: B
Explanation:
The optimal method for collecting frequent patient-reported pain data is through electronic Patient-Reported Outcomes (ePRO) with built-in reminder functionality.
According to the GCDMP (Chapter: Electronic Data Capture Systems), ePRO systems provide a validated, real-time, and user-friendly interface for subjects to record time-sensitive data accurately. The use of automated reminders ensures compliance with protocol-specified data collection times, improving data completeness and accuracy.
Paper diaries (option A) are prone to recall bias and backfilling, while daily site calls (option B) are resource-intensive and introduce human error. IVRS systems (option C) are acceptable but less efficient and user-friendly than modern ePRO applications, which can integrate timestamp validation, compliance monitoring, and real-time alerts.
ePRO systems also comply with FDA 21 CFR Part 11 and ICH E6 (R2) for audit trails, authentication, and validation, making them the preferred solution for repeated PRO data collection.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC) Systems, Section 6.1 - Use of ePRO for Repeated Measures FDA Guidance for Industry: Electronic Source Data in Clinical Investigations, Section 5 - ePRO Compliance and Validation ICH E6 (R2) GCP, Section 5.5.3 - Electronic Data Systems and Recordkeeping
NEW QUESTION # 95
Which is the best way to see site variability in eligibility screening?
- A. List eligibility waivers by site
- B. Graph enrollment by site
- C. Plot eligibility rate by site
- D. Summarize screening rate by site
Answer: C
Explanation:
To identify site variability in eligibility screening, the most effective approach is to plot eligibility rate by site. This allows visual detection of differences in how well each site screens subjects according to protocol-defined inclusion and exclusion criteria.
The GCDMP (Chapter: Data Quality Assurance and Metrics) emphasizes the importance of graphical analysis for identifying anomalies and site-level performance variability. By plotting the eligibility rate by site, data managers and clinical operations teams can quickly identify outliers-sites that screen too many or too few eligible subjects-indicating potential training issues, misunderstanding of inclusion/exclusion criteria, or even possible protocol deviations.
While summarizing screening rate (B) provides useful numeric data, it lacks visual comparability. Listing waivers (A) or enrollment counts (C) provide limited insights into eligibility consistency.
Therefore, option D-Plot eligibility rate by site-is the best analytic and visualization practice to assess site variability in screening outcomes.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Quality Assurance and Control, Section 6.1 - Use of Metrics and Graphical Review for Site Performance ICH E6(R2) GCP, Section 5.18.4 - Identification of Systematic or Site-Specific Issues
NEW QUESTION # 96
......
Latest 100% Passing Guarantee - Brilliant CCDM Exam Questions PDF: https://examtorrent.testkingpdf.com/CCDM-testking-pdf-torrent.html
